TJ272B - Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition - Google Patents

Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition

Info

Publication number
TJ272B
TJ272B TJ96000367A TJ96000367A TJ272B TJ 272 B TJ272 B TJ 272B TJ 96000367 A TJ96000367 A TJ 96000367A TJ 96000367 A TJ96000367 A TJ 96000367A TJ 272 B TJ272 B TJ 272B
Authority
TJ
Tajikistan
Prior art keywords
compounds
quinazoline compounds
pharmaceutical
acceptable salts
pharmaceutical composition
Prior art date
Application number
TJ96000367A
Other languages
English (en)
Inventor
Stephen Webber
Ted M Bleckman
John Attard
Terence R Jones
Michael D Varney
Original Assignee
Agouron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharma filed Critical Agouron Pharma
Publication of TJ272B publication Critical patent/TJ272B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TJ96000367A 1992-03-31 1993-03-26 Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition TJ272B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/861,030 US5430148A (en) 1992-03-31 1992-03-31 Antiproliferative quinazolines
PCT/US1993/002636 WO1993020055A1 (fr) 1992-03-31 1993-03-26 Quinazolines anti-proliferatives

Publications (1)

Publication Number Publication Date
TJ272B true TJ272B (en) 2000-10-05

Family

ID=25334675

Family Applications (1)

Application Number Title Priority Date Filing Date
TJ96000367A TJ272B (en) 1992-03-31 1993-03-26 Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition

Country Status (20)

Country Link
US (3) US5430148A (fr)
EP (1) EP0637300B1 (fr)
JP (1) JP3272357B2 (fr)
KR (1) KR100226114B1 (fr)
AT (1) ATE205197T1 (fr)
AU (1) AU681075B2 (fr)
CA (2) CA2132514C (fr)
DE (1) DE69330715T2 (fr)
DK (1) DK0637300T3 (fr)
ES (1) ES2162818T3 (fr)
FI (1) FI113765B (fr)
HU (1) HU222523B1 (fr)
MD (1) MD1638G2 (fr)
NO (1) NO307829B1 (fr)
NZ (1) NZ251804A (fr)
PT (1) PT637300E (fr)
RU (1) RU2135481C1 (fr)
SG (2) SG46672A1 (fr)
TJ (1) TJ272B (fr)
WO (1) WO1993020055A1 (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
US5756502A (en) * 1994-08-08 1998-05-26 Warner-Lambert Company Quinazolinone derivatives as cholyecystokinin (CCK) ligands
US5593999A (en) * 1995-06-07 1997-01-14 Nair; Madhavan G. Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
US5783577A (en) * 1995-09-15 1998-07-21 Trega Biosciences, Inc. Synthesis of quinazolinone libraries and derivatives thereof
WO1997042192A1 (fr) * 1996-05-07 1997-11-13 Basf Aktiengesellschaft Imidazoquinazolines, agents les contenant et leur utilisation dans la lutte contre les champignons nuisibles et les parasites animaux
AR012634A1 (es) * 1997-05-02 2000-11-08 Sugen Inc Compuesto basado en quinazolina, composicion famaceutica que lo comprende, metodo para sintetizarlo, su uso, metodos de modulacion de la funcion deserina/treonina proteinaquinasa con dicho compuesto y metodo in vitro para identificar compuestos que modulan dicha funcion
CN1307421C (zh) * 1997-08-08 2007-03-28 塞米得肿瘤学美国公司 克服生物及化学治疗抗性的方法与组合物
DE69900841T2 (de) 1998-01-23 2002-10-02 Newbiotics Inc Durch enzymkatalyse erhaltene therapeutische substanzen.
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
US6706721B1 (en) * 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CN1391486A (zh) 1999-07-22 2003-01-15 新生物公司 治疗对治疗有抗性的肿瘤的方法
US6683061B1 (en) 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
US7230000B1 (en) 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US7087613B2 (en) * 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (uk) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
BR0114713A (pt) * 2000-10-16 2004-01-13 Neopharm Inc Formulação lipossÈmica de mitoxantrona
US6486199B1 (en) 2001-06-21 2002-11-26 Medicines For Malaria Venture Mmv International Centre Cointrin Spiro and dispiro 1,2,4-trioxolane antimalarials
WO2003043995A1 (fr) * 2001-11-20 2003-05-30 Cytokinetics, Inc. Procede de racemisation de quinazolinones chirales
AU2003213092A1 (en) * 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
WO2003097053A1 (fr) 2002-05-09 2003-11-27 Cytokinetics, Inc. Composes, compositions et procedes
CA2485148A1 (fr) * 2002-05-09 2003-11-20 Cytokinetics, Inc. Composes, compositions et procedes
WO2003103575A2 (fr) * 2002-05-23 2003-12-18 Cytokinetics, Inc. Composes, compositions et procedes
EP1556357A4 (fr) * 2002-06-14 2006-09-13 Cytokinetics Inc Composes, compositions et procedes
US7371778B2 (en) * 2002-06-21 2008-05-13 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US6906205B2 (en) * 2002-06-21 2005-06-14 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US20080125441A1 (en) * 2002-06-21 2008-05-29 Medicines For Malaria Venture Mmv Spiro and dispiro 1,2,4-trioxolane antimalarials
US7211580B2 (en) * 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
AU2003262747A1 (en) * 2002-08-21 2004-03-11 Cytokinetics, Inc. Compounds, compositions, and methods
US7557115B2 (en) * 2002-09-30 2009-07-07 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005032481A2 (fr) * 2003-09-30 2005-04-14 Scios Inc. Dérivés de quinazoline en tant que médicaments
EP1682534A2 (fr) * 2003-11-03 2006-07-26 Cytokinetics, Inc. Derives de pyrimidin-4-one, compositions et methodes
WO2005046588A2 (fr) * 2003-11-07 2005-05-26 Cytokinetics, Inc. Composes, compositions et methodes
JP2007513154A (ja) * 2003-12-08 2007-05-24 サイトキネティクス・インコーポレーテッド 化合物、組成物及び方法
CA2591948C (fr) * 2005-01-19 2013-11-12 Rigel Pharmaceuticals, Inc. Promedicaments de composes de 2,4-pyrimidinediamine et leurs utilisations
US8067620B2 (en) * 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
CN1303080C (zh) * 2005-07-18 2007-03-07 康辰医药发展有限公司 盐酸洛拉曲克的合成工艺
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CN101353343B (zh) * 2007-07-27 2012-07-04 上海医药工业研究院 高纯度盐酸诺拉曲塞二水合物的制备方法
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP5756096B2 (ja) * 2009-06-12 2015-07-29 ソックプラ−シアンセ エ ジェニー エス．ウ．セ． グアニンリボスイッチ結合化合物及び抗生物質としてのその使用
PL2513115T3 (pl) 2009-12-18 2014-04-30 Basilea Pharmaceutica Ag Antybiotyki tricykliczne
EP2721034B1 (fr) 2011-06-17 2016-07-20 Basilea Pharmaceutica AG Antibiotiques n-hétérotricycliques
RU2507198C1 (ru) * 2012-09-10 2014-02-20 Владимир Иванович Петров Производные хиназолина, обладающие ноотропной и антигипоксической активностью
RU2507199C1 (ru) * 2012-09-10 2014-02-20 Владимир Иванович Петров Производные хиназолина, обладающие антидепрессивной, анксиолитической и ноотропной активностью
RU2622638C1 (ru) * 2016-07-14 2017-06-19 Владимир Иванович Петров Производные хиназолин-4(3н)-она, обладающие нейро- и кардиопротекторной активностью
SG11202108333YA (en) 2019-02-14 2021-08-30 Som Innovation Biotech S A Triamterene or nolatrexed for use in the treatment of phenylketonuria

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1817982A (en) * 1931-08-11 Winfrid hentrich and max habdtmann
CA793845A (en) * 1968-09-03 Davoll John Amine compounds and production thereof
GB206565A (en) * 1922-08-03 1923-11-05 Walter Wood Tullis Improvements in or relating to the concentration and preparation for smelting of iron ores
GB1045180A (en) * 1963-09-20 1966-10-12 Parke Davis & Co Quinazoline derivatives
GB1212613A (en) * 1967-02-28 1970-11-18 Chinoin Gyogyszer Es Vegyeszet 4-quinazolone derivatives and process for the preparation thereof
GB1161644A (en) * 1967-09-11 1969-08-13 Parke Davis & Co Quinazoline Compounds and process means for producing the same
US4048312A (en) * 1973-10-30 1977-09-13 Eli Lilly And Company 2,4-Diaminoquinazolines as antithrombotic agents
IT1050750B (it) * 1975-12-05 1981-03-20 Erba Carlo Spa Derivati della 3.4 di idro chinazolina
US4223143A (en) * 1978-12-11 1980-09-16 Siegfried Aktiengesellschaft Quinazoline derivatives
US4391809A (en) * 1979-10-15 1983-07-05 Warner-Lambert Company Methods for treating psoriasis
DE3069468D1 (en) * 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
US4853221A (en) * 1980-11-13 1989-08-01 Warner-Lambert Company Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
JPS57156467A (en) * 1981-03-20 1982-09-27 Asahi Chem Ind Co Ltd 2,4-disubstituted-6-quinazolinesulfonamide derivative
JPS6136273A (ja) * 1984-07-26 1986-02-20 Mitsubishi Yuka Yakuhin Kk ２−フエニルアルキル−４（３ｈ）−キナゾリノン誘導体
US4749698A (en) * 1985-07-08 1988-06-07 Rorer Pharmaceutical Corporation Antihypertensive derivatives
GB8513754D0 (en) * 1985-05-31 1985-07-03 Jones T R Anti-cancer quinazoline derivatives
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
US4857530A (en) * 1987-11-03 1989-08-15 Warner-Lambert Company Substituted quinazolinones as anticancer agents
GB8809978D0 (en) * 1988-04-27 1988-06-02 Ici Plc Anti-tumour agents
EP0365763A1 (fr) * 1988-09-30 1990-05-02 Agouron Pharmaceuticals, Inc. Composés cycliques antiproléfératifs
GB8829296D0 (en) * 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
NO171069C (no) * 1990-05-29 1993-01-20 Protan Biopolymer As Kovalent tverrbundne, sterkt svellende alkalimetall- og ammonium-alginatgeler, samt fremgangsmaate for fremstilling derav
ZA913730B (en) * 1990-05-30 1992-02-26 Ici Plc Anti-tumor compounds
US5430148A (en) * 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines

Also Published As

Publication number Publication date
KR100226114B1 (ko) 1999-10-15
NZ251804A (en) 1997-06-24
HU9402799D0 (en) 1994-12-28
RU94045251A (ru) 1996-07-20
AU681075B2 (en) 1997-08-21
CA2474211A1 (fr) 1993-10-14
US5885996A (en) 1999-03-23
MD1638F2 (en) 2001-03-31
JPH07505395A (ja) 1995-06-15
FI113765B (fi) 2004-06-15
EP0637300A1 (fr) 1995-02-08
RU2135481C1 (ru) 1999-08-27
HUT68580A (en) 1995-06-28
DK0637300T3 (da) 2001-12-10
DE69330715D1 (de) 2001-10-11
SG93183A1 (en) 2002-12-17
CA2474211C (fr) 2006-10-03
CA2132514C (fr) 2004-10-26
WO1993020055A1 (fr) 1993-10-14
HU222523B1 (hu) 2003-08-28
ATE205197T1 (de) 2001-09-15
JP3272357B2 (ja) 2002-04-08
US5707992A (en) 1998-01-13
DE69330715T2 (de) 2002-02-14
MD1638G2 (ro) 2001-09-30
US5430148A (en) 1995-07-04
ES2162818T3 (es) 2002-01-16
SG46672A1 (en) 1998-02-20
FI944525A (fi) 1994-09-29
NO307829B1 (no) 2000-06-05
FI944525A0 (fi) 1994-09-29
AU3966493A (en) 1993-11-08
CA2132514A1 (fr) 1993-10-14
PT637300E (pt) 2002-01-30
EP0637300B1 (fr) 2001-09-05
NO943629L (no) 1994-09-29
NO943629D0 (no) 1994-09-29

Similar Documents

Publication Publication Date Title
TJ272B (en) Quinazoline compounds or their pharmaceutical acceptable salts and pharmaceutical composition
BG104356A (en) Compounds based on azabenzimidazole for the modulation of serin/treonin protein kinase function
CA2129489A1 (fr) Methode et composition inhibant la croissance de microorganismes, comportant de l'acide peracetique et un biocide non oxydant
CA2236160A1 (fr) Methode et composition pour empecher la multiplication des microorganismes comprenant de l'acide peracetique et un biocide non-oxydant
CA2190324A1 (fr) Methode et composition pour empecher la croissance de microorganismes, grace a l'utilisation d'acide peracetique et d'un biocide non oxydant
CA2334907A1 (fr) Procede et composition utiles pour inhiber la croissance des micro-organismes comprenant de l'acide peracetique et un biocide non oxydant
PL316033A1 (en) Acidified nitrite as an agent against micro-organisms
WO2000034265A3 (fr) Agents antimicrobiens quinoleine-indole, et utilisations et compositions associees
GEP20063885B (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
HU9501146D0 (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives with kynureninase and/or kynurenine-3-hydroxylase inhibiting activity
WO1999067238A3 (fr) Agents antimicrobiens di- et tetra-hydroquinoline-indol, utilisations et compositions correspondantes
UA41285C2 (uk) Креатин фосфат і його фармацевтично прийнятні солі для лікування пухлин та фармацевтична композиція, що має протипухлинну активність
AU2267899A (en) Fungi of the genus piriformospora
YU155791A (sh) Antiproliferativna supstituisana triciklična jedinjenja
EP0333000A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
ZA933251B (en) Halogenated 4'-methozyacetophenones as microbicides and preservatives
CA2335397A1 (fr) Methode de selection de composes pouvant inhiber la neoplasie et compositions pharmaceutiques contenant de tels composes
YU154091A (sh) Antiproliferativna supstituisana naftalenska jedinjenja
EP0332999A3 (en) Peptides with inhibitory activity of enzymatic systems, process for their preparation and pharmaceutical compositions containing them
WO1987001279A3 (fr) Derives anti-tumoraux de chamigrene et leurs procedes d'utilisation
MX9603754A (es) Compuestos, de amplio espectro, activos contra microbios.
MX9603535A (es) Nitrito acido como un agente antimicrobiano.
NZ500671A (en) Stable crystalline hydrochloride and hydrobromide salts of swainsonine and use in the treatment of fungal, bacterial and viral diseases